Full-Time

Medical Director

Clinical Development

Confirmed live in the last 24 hours

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

51-200 employees

Develops treatments for neurodegenerative diseases

Senior, Expert

No H1B Sponsorship

Cambridge, MA, USA

Must reside and work within the United States, in a state where Amylyx currently does business. Required to travel to the corporate location in Cambridge, MA several times a year.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • MD required
  • 2+ years of experience in leading clinical development programs in the biotechnology/pharmaceutical industry with a proven record of achievements.
  • Ability to think critically and demonstrate troubleshooting and problem-solving skills.
  • Demonstrated leadership and team building skills as well as the ability to perform effectively in a multi-disciplinary environment.
  • Ability to lead directly and by influence, including strong interpersonal, problem solving, conflict resolution and analytical skills in a matrix environment.
  • Excellent communication skills (oral and written) and organizational skills.
  • Ability to travel internationally and domestically
Responsibilities
  • Provides medical monitoring to assigned clinical trials in the arenas of serious and fatal neurodegenerative diseases and endocrine conditions.
  • Provides clinical development leadership for programs that integrate extensive knowledge in clinical science and neurology or endocrinology, and inputs from the global medical and patient communities.
  • Works closely with Medical Directors, Pharmacology, Drug Discovery, external experts, and investigators to accumulate scientific and medical knowledge necessary to support clinical development plans with a focus on pharmacodynamic endpoints.
  • Integrates scientific rationale, regulatory requirements, product development plan, and value to patients and shareholders to build a solid Clinical Development Plan (CDP).
  • Accountable for production of highest quality program related documents, including protocols, IBs, clinical study reports, briefing documents and drug labels.
  • Develops and maintains relationships with program counterparts in Research, Regulatory Affairs, Clinical Operations, Statistics and Contract Research Organizations (CROs).
  • Acts as the primary Clinical Development interface with internal stake holders as well as external subject matter experts and alliance partners for the assigned programs.
  • Contributes to specific Business Development activities and various organizational initiatives in Clinical Development
Desired Qualifications
  • Background in translational science is a plus.
Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

View

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials to assess its effectiveness. The CENTAUR ALS trial showed promising results for ALS patients, using a randomized, double-blind, placebo-controlled design to ensure reliable outcomes. They are also conducting the PEGASUS trial to evaluate AMX0035's safety and effectiveness in Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes.

Company Size

51-200

Company Stage

IPO

Total Funding

$166.7M

Headquarters

Cambridge, Massachusetts

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • Positive Phase II results for AMX0035 in ALS boost credibility.
  • Growing demand for personalized medicine benefits Amylyx's tailored treatment plans.
  • Increased collaboration with academic institutions offers new research opportunities.

What critics are saying

  • Phase III PHOENIX trial failure raises concerns about ALS treatment efficacy.
  • Leadership changes may disrupt clinical development strategies.
  • Low share price public offering suggests potential financial strain.

What makes Amylyx Pharmaceuticals unique

  • Amylyx focuses on neurodegenerative diseases like ALS and Alzheimer's.
  • AMX0035 is a flagship product under rigorous clinical evaluation.
  • Amylyx engages in community awareness campaigns for neurodegenerative diseases.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

10%

2 year growth

11%
Business Wire
Feb 18th, 2025
Nura Bio Expands Leadership Team with C-Suite Appointments

Lahar Mehta, M.D. Lahar Mehta, M.D., joins Nura Bio from Amylyx Pharmaceuticals, where he was Senior Vice President/Head, Global Clinical Development, leading clinical development and clinical pharmacology activities across several indications including amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP), and Wolfram syndrome.

ETF Daily News
Jan 13th, 2025
Amylyx Pharmaceuticals Enters Underwriting Agreement for Public Offering

On January 10, 2025, Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced its entry into an underwriting agreement with Leerink Partners LLC for the issuance and sale of 17,142,857 shares of its common stock at a price of $3.50 per share.

Business Wire
Jan 11th, 2025
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an underwritten public offering of 17,142,857 s

CityBiz
Jan 6th, 2025
Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer

Amylyx Pharmaceuticals appoints Dan Monahan as Chief Commercial Officer.

TipRanks
Dec 30th, 2024
Amylyx Partners with Gubra for GLP-1 Antagonist

Amylyx partners with Gubra for GLP-1 antagonist.